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The peptidylarginine deiminases PAD2 and PAD4 are implicated in the pathogenesis of
several autoimmune diseases. PAD4 may be pathogenic in systemic lupus erythematosus
(SLE) through its role in neutrophil extracellular trap (NET) formation that promotes
autoantigen externalization, immune dysregulation, and organ damage. The role of this
enzyme in mouse models of autoimmunity remains unclear, as pan-PAD chemical inhibitors
improve clinical phenotype, whereas PAD4-KO models have given conflicting results. The
role of PAD2 in SLE has not been investigated. The differential roles of PAD2 and PAD4 in
TLR-7–dependent lupus autoimmunity were examined. Padi4–/– displayed decreased
autoantibodies, type I IFN responses, immune cell activation, vascular dysfunction, and
NET immunogenicity. Padi2–/– mice showed abrogation of Th subset polarization, with
some disease manifestations reduced compared with WT but to a lesser extent than
Padi4–/– mice. RNA sequencing analysis revealed distinct modulation of immune-related
pathways in PAD-KO lymphoid organs. Human T cells express both PADs and, when
exposed to either PAD2 or PAD4 inhibitors, displayed abrogation of Th1 polarization.
These results suggest that targeting PAD2 and/or PAD4 activity modulates dysregulated
TLR-7–dependent immune responses in lupus through differential effects of innate and
adaptive immunity. Compounds that target PADs may have potential therapeutic roles in T
cell–mediated diseases.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune syndrome characterized by profound 
immune dysregulation affecting innate and adaptive immunity. SLE manifests with pleiotropic clinical man-
ifestations, generation of  autoantibodies against nuclear antigens, and the development of  immune complex-
es (ICs) that stimulate type I IFN production by plasmacytoid DCs (pDCs) (1). Type I IFNs play important 
roles in the development, progression, and clinical manifestations of  SLE (2). In SLE, there is also a striking 
increase in the development of  cardiovascular (CV) complications due to accelerated atherosclerosis, which 
represents an important cause of  morbidity and mortality (3). Significant abnormalities in myeloid cells, 
pDCs, and lymphocytes are detected in human SLE and in murine models of  the disease (1, 4). Therefore, 
identifying putative pharmacologic targets that decrease autoantigen generation and modulate immune dys-
regulation in SLE is needed. While several available therapies are effective in mitigating SLE manifestations, 
many of  them are associated with significant side effects due to a lack of  specificity, while other more target-
ed treatments may not address all the pathogenic immune features that contribute to this complex syndrome.
Protein citrullination is the process by which the basic amino acid residue arginine is converted into the 
neutral residue citrulline (5). This reaction is catalyzed by a family of  calcium-dependent enzymes called 
peptidylarginine deiminases (PADs), of  which there are 5 isozymes (PAD1–4 and PAD6) encoded by distinct 
genes in the human genome (5). These isozymes have unique tissue localization and overlapping substrates, 
The peptidylarginine deiminases PAD2 and PAD4 are implicated in the pathogenesis of several 
autoimmune diseases. PAD4 may be pathogenic in systemic lupus erythematosus (SLE) through 
its role in neutrophil extracellular trap (NET) formation that promotes autoantigen externalization, 
immune dysregulation, and organ damage. The role of this enzyme in mouse models of 
autoimmunity remains unclear, as pan-PAD chemical inhibitors improve clinical phenotype, 
whereas PAD4-KO models have given conflicting results. The role of PAD2 in SLE has not been 
investigated. The differential roles of PAD2 and PAD4 in TLR-7–dependent lupus autoimmunity 
were examined. Padi4–/– displayed decreased autoantibodies, type I IFN responses, immune cell 
activation, vascular dysfunction, and NET immunogenicity. Padi2–/– mice showed abrogation of Th 
subset polarization, with some disease manifestations reduced compared with WT but to a lesser 
extent than Padi4–/– mice. RNA sequencing analysis revealed distinct modulation of immune-
related pathways in PAD-KO lymphoid organs. Human T cells express both PADs and, when exposed 
to either PAD2 or PAD4 inhibitors, displayed abrogation of Th1 polarization. These results suggest 
that targeting PAD2 and/or PAD4 activity modulates dysregulated TLR-7–dependent immune 
responses in lupus through differential effects of innate and adaptive immunity. Compounds that 
target PADs may have potential therapeutic roles in T cell–mediated diseases.
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and there is 70%–95% homology in their amino acid sequence among mammals. PADs are involved in vari-
ous important physiological processes, including immune responses, cell signaling, and gene expression regu-
lation. Abnormal protein citrullination and/or aberrant immune responses to citrullinated antigens have been 
implicated in the pathogenesis of  various cancers and autoimmune and neurological diseases (6–9).
Intracellular citrullination may occur as part of  the physiological function of  PADs and has been best 
described for PAD4. PAD4 appears to be the main member of  the PAD family with a nuclear localization 
signal, and its enzymatic activity impacts gene expression by directly citrullinating transcription factors 
or by regulating chromatin structure through histone citrullination (10, 11). PAD4 is expressed at high 
levels in neutrophils, and histone citrullination mediated by PAD4 has been implicated in the formation 
of  neutrophil extracellular traps (NETs) following certain types of  stimulation (12–14). NET formation is 
a mechanism of  neutrophil cell death whereby, following a complex and still incompletely characterized 
intracellular pathway, these cells extrude a meshwork of  nuclear material bound to granule proteins to the 
extracellular space (15). While this process is considered an important antimicrobial strategy, dysregula-
tion in NET formation has recently been implicated in the pathogenesis of  systemic autoimmune diseases 
including rheumatoid arthritis (RA) (7, 16, 17), psoriasis (18), systemic vasculitis (19), and SLE (20–22). 
An imbalance of  NET formation and degradation occurs in SLE, and this phenomenon may play a role in 
augmenting the half-life of  externalized modified autoantigens that, in a predisposed host, would contrib-
ute to fueling the immune system, which would promote type I IFN responses, inflammasome activation, 
aberrant adaptive immunity, and tissue damage, including vascular injury (20, 21, 23–25). In addition to the 
role in NET formation, PAD4 enhances the activity of  NF-κB in neutrophils, independently of  changes in 
histone citrullination, with potential therapeutic implications for TLR-mediated inflammation (26).
PAD2 is the other PAD isozyme that is expressed at high levels in some immune cell subsets, primarily 
monocytes and macrophages, but is also described in neutrophils (27, 28). However, the role of  PAD2 in 
autoimmune and inflammatory diseases in general, and SLE in particular, is less clear. In specific models 
of  arthritis, PAD2 is not required for NET formation but can potentially modify immune responses by 
citrullinating cytokines like TNF-α (29). Recent studies suggest that PADs may potentially impact T cell 
biology, as PAD4-KO mouse T cells lose citrullinated histone H3 (Cit-H3) staining upon activation. Fur-
thermore, PAD2- and PAD4-mediated citrullination can modulate Th2 and Th17 cytokine expression (30).
These observations indicate that PAD2 and PAD4 may play important and distinct roles in the modulation 
of aberrant immune responses in autoimmune conditions. The roles of PAD2 and PAD4 in SLE pathogenesis, 
however, remain unclear, primarily because of conflicting results in various murine models. Systemic adminis-
tration of chemical inhibitors targeting both PAD2 and PAD4 can significantly abrogate lupus phenotype and 
associated immune dysregulation and organ damage in 2 genetically prone mouse models of lupus, NZM2328 
and MRL/lpr (31, 32). These compounds can also modulate vasculopathy and thrombosis in lupus and athero-
sclerosis models (31, 33). In contrast, MRL/lpr mice that genetically lack PAD4 are not protected from disease 
(34), while pristane-induced lupus is exacerbated in PAD4-KO mice (35). The reasons for these discrepancies 
are not clear and may be related to the dual inhibition of PAD2 and PAD4 with the chemical inhibitors, off-tar-
get effects of the inhibitors, the intricacies of the specific genetic models, putative antiinflammatory effects of  
PADs (36), differences in microbiome, or the impact of partial inhibition versus complete inhibition of PAD 
activity. It has also been observed that redundancy exists in the effect of the PADs on various cellular functions, 
and how PADs regulate each other remains unclear (30). These observations support that mouse models of  
lupus, similar to human disease, are heterogeneous and driven by different pathways and that understanding 
the roles of the PADs in various aspects of immune dysregulation and organ damage is crucial in assessing 
whether targeting these enzymes represents a viable option in the treatment of autoimmune diseases.
In SLE, the dosage of  the endosomal TLR-7 has been proposed to be crucial in disease pathogenesis 
in humans and mice. TLR-7 overexpression induces spontaneous lupus-like disease, while suppressing sig-
naling through this TLR in lupus-prone mice hampers disease development (37–40). Given that the role of  
PAD2 in SLE animal models has not been addressed and that the exact role of  PAD4 inhibition remains to 
be further elucidated, we investigated the role of  these 2 isozymes in an induced model of  TLR-7–depen-
dent lupus-like autoimmunity in the absence of  confounding murine autoimmunity susceptibility genes. 
We found differential effects of  PAD2 and PAD4 on the induction of  immune dysregulation, tissue dam-
age, endothelial dysfunction, immune cell gene expression profiles, and autoimmunity features. We also 
describe how these PADs modulate NET immunogenicity and T cell responses, and we demonstrate that 
selective inhibitors of  PAD2 and PAD4 also affect human T cell function.
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Results
PAD2 and PAD4 differentially regulate TLR-7–mediated lupus autoimmunity. To examine the differential role of  
different PADs in SLE progression independently of  contributions by murine lupus susceptibility genes, a 
previously described inducible model of  TLR-7–dependent lupus-like disease was used (41). WT, Padi2–/–, 
and Padi4–/– mice (all in FVB background) were exposed epicutaneously to the TLR-7 agonist imiquimod 
for 6 weeks, 3 times a week, as described (41). During the third week of  treatment, the mice were exposed 
to a subacute dose of  ultraviolet B ray–narrowband (UVB-narrowband) radiation for 5 consecutive days. 
Although no weight loss developed at the experimental endpoint, imiquimod-treated WT — and, to a 
lesser extent, imiquimod-treated Padi2–/– mice but not Padi4–/– mice — showed signs of  physical discomfort 
and reduced grooming. Furthermore, treated WT and Padi2–/– mice displayed significant increases in spleen 
size and spleen weight when compared with untreated mice. In contrast, spleen size was significantly lower 
in the imiquimod-treated Padi4–/– mice when compared with WT-treated mice (Figure 1A). While quanti-
fication of  serum anti-dsDNA, a lupus-specific autoantibody, revealed that imiquimod-treated mice — in 
all 3 groups — had significantly higher antibody titers than untreated mice (Figure 1B), levels of  these 
antibodies were approximately 2-fold higher in WT FVB when compared with Padi2–/– and Padi4–/– mice 
(Figure 1B). When additional lupus autoantibodies were measured, anti–ribonucleoprotein/Smith antigen 
(anti-RNP/Sm) serum levels did not differ across the 3 groups, while anti-histone antibodies were signifi-
cantly decreased in Padi4–/– and there was a trend for lower levels in the Padi2–/– when compared with WT 
mice (P = 0.079, Supplemental Figure 1; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.124729DS1). In contrast, no differences were observed in total serum IgG lev-
els (Figure 1C). These results indicate expansion of  specific autoreactive antibody–producing cells in FVB 
mice upon exposure to a TLR-7 agonist and modulation of  these responses by PADs. Nonsignificant alter-
ations in frequency of  circulating immune cells were observed to varying degrees in imiquimod-treated 
WT and Padi2–/– mice, including increased lymphocyte, monocyte, and neutrophil frequencies, but not 
in Padi4–/– mice (Supplemental Figure 2, A–C). Gene expression analyses of  splenocytes demonstrated 
enhanced upregulation of  type I IFN–regulated genes in imiquimod-treated FVB but not in treated Padi2–/– 
or Padi4–/– mice (Figure 1D). Overall, while topical imiquimod administration resulted in significant sys-
temic inflammation and lupus-like features in WT FVB mice, similar to what has been reported for other 
nonautoimmune mouse strains (41), these features were significantly attenuated in Padi4–/– mice and — to 
a somewhat lesser extent — in Padi2–/– mice.
PADs modulate kidney IC deposition in TLR-7–mediated lupus autoimmunity. In contrast to a previous report 
(41), administration of  imiquimod to FVB mice did not result in significant albuminuria (Supplemental Fig-
ure 2D) or in significant changes in the renal histopathologic score (data not shown). However, immunoflu-
orescence analysis of  kidney sections revealed moderate to severe C3 and IgG deposition in the glomeruli 
of  imiquimod-treated WT FVB mice (Figure 2, A and B). While glomerular IC deposition was only slightly 
reduced in treated Padi2–/– mice, the Padi4–/– mice exposed to imiquimod were significantly protected from 
glomerular IgG deposition when compared with both WT and Padi2–/– mice (Figure 2, A and B). These 
results suggest that immune mechanisms controlled by PAD4 activity — and, to a lesser extent, PAD2 — 
either directly or indirectly promote renal IC deposition in response to proinflammatory stimuli.
Padi4–/–, but not Padi2–/–, mice are protected from endothelial dysfunction in TLR-7–mediated lupus autoim-
munity. Endothelial dysfunction and vascular damage are common features of  murine and human SLE 
and contribute to heightened morbidity and mortality in this disease (3). To test whether topical imiquim-
od administration triggers vasomotor dysfunction in these strains, we measured acetylcholine-dependent 
(Ach-dependent) vasorelaxation responses in thoracic aortas from untreated and imiquimod-treated WT 
FVB, Padi2–/–, and Padi4–/– mice. Treated WT FVB and Padi2–/– mice displayed significantly impaired endo-
thelium-dependent vasorelaxation compared with untreated mice. In contrast, Padi4–/– mice were protect-
ed from developing endothelial dysfunction by imiquimod (Figure 3). These data implicate PAD4-related 
pathways in endothelial dysfunction characteristic of  lupus autoimmunity.
Padi4–/– NETs decreased vasculopathic and immunostimulatory effects. We and others have demonstrated that 
NETs can induce and amplify pathogenic type I IFN responses and promote vascular damage in SLE and 
atherosclerosis models (20, 33, 42, 43). Given the putative role of  PADs in NET formation (13), we sought 
to determine whether the differences observed in disease progression among the different mouse groups 
were due to differential effects on the ability of  neutrophils to form NETs in the presence or absence of  
PADs. While Padi4–/– neutrophils produced fewer NETs in response to the ionophore A223817, NETs were 
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still present in these mice when compared with stimulated WT FVB and Padi2–/– neutrophils (Figure 4). 
However, Cit-H3 was undetectable in NETs from Padi4–/– mice, while other essential NET components 
such as DNA and myeloperoxidase (MPO) were detected. Of  note, glycolysis, the main metabolic pathway 
utilized by neutrophils, was not impaired in Padi4–/– neutrophils compared with WT FVB and Padi2–/– 
neutrophils (Supplemental Figure 3), suggesting that their reduced capacity to form NETs is not due to an 
inability to generate ATP required for NET formation. Previous studies indicated that PAD2 may have the 
ability to localize to the nucleus and citrullinate histones (44). However, Padi2–/– neutrophils did not display 
impairment in their ability to form NETs, and there were no reductions in Cit-H3 (Figure 4).
To mimic the in vivo setting in subsequent in vitro studies, we stimulated WT FVB, Padi2–/–, and Padi4–/– 
neutrophils with imiquimod to assess NET induction. Protein analysis of  imiquimod-induced NETs con-
firmed that PAD4 is the main isoform responsible for Cit-H3 generation in mouse neutrophils (Figure 4C). 
Since NETs still formed in Padi2–/–, and to lesser extent in Padi4–/–, we examined whether the vasculoprotec-
tive phenotype of  imiquimod-treated Padi4–/– mice was due to differences in the quality of  Padi4–/– NETs. 
WT FVB aortic rings were exposed to equal concentrations of  imiquimod-generated NETs purified from 
Figure 1. Padi2 and Padi4 deficiencies differentially modulate TLR-7–induced autoimmunity. (A) Quantification of splenomegaly assessed by spleen 
weight (% of body weight) in untreated (white bars) and imiquimod-treated (black bars) WT FVB, Padi2–/–, and Padi4–/– mice; n = 10–15 mice/group. Compiled 
data from 3 independent experiments. (B and C) Levels of circulating anti-dsDNA autoantibodies (B) and total IgG (C) in untreated (white whisker plots) and 
imiquimod-treated (black whisker plots) FVB, Padi2–/–, and Padi4–/– mice. n = 9–15 mice/group. Compiled data from 3 independent experiments. (D) Gene 
expression data of splenocytes from treated FVB, Padi2–/–, and Padi4–/– mice normalized to gene expression in the corresponding control mice. n = 7 mice/
group. Compiled data from 2 independent experiments. Box-and-whisker plots show median, lower and upper quartiles, and minimum and maximum val-
ues. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001. Statistical analysis was performed by 2-tailed Mann-Whitney U test. IMQ, imiquimod.
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neutrophils from the 3 different strains. Similar to the in vivo observations, WT FVB and Padi2–/– NETs 
directly impaired endothelium-dependent vasorelaxation, whereas equal amounts of  Padi4–/– NETs did not 
(Figure 4D). To assess whether the quality of  the NETs generated by Padi2–/– or Padi4–/– would impact the 
ability of  these NETs to induce type I IFN responses in target cells, we incubated FVB mouse splenocytes 
with imiquimod-induced NETs from WT, Padi2–/–, and Padi4–/– mice and quantified induction of  type I 
IFN–regulated genes (Figure 4E). FVB NETs led to the strongest induction of  these genes when compared 
with Padi2–/– and Padi4–/– NETs (Figure 4E). Overall, these data indicate that specific modifications of  the 
Figure 2. Renal immune complex deposition is attenuated in imiquimod-treated Padi4–/–mice. (A and B) Frozen 
kidney sections were stained for immune complex deposition (A) and quantified based on fluorescence intensity and 
staining pattern (B); n = 3 mice/group. Box-and-whisker plots show median, lower and upper quartiles, and minimum 
and maximum score values. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001. Statistical analysis was performed 
by 2-tailed unpaired t test. Green represents C3, red represents IgG, and blue represents DAPI. The figures on the right 
are merged images. Total magnification is 40×.
6insight.jci.org   https://doi.org/10.1172/jci.insight.124729
R E S E A R C H  A R T I C L E
content of  the NETs may regulate the degree of  immune cell stimulation and endothelial dysfunction medi-
ated by these structures and that only PAD4 influences the vasculopathic effects of  NETs, whereas both 
PAD4 and PAD2 modulate the interferogenic properties of  NETs.
Differential secondary lymphoid organ gene regulation in Padi2–/– and Padi4–/– mice in response to TLR-7 activation. 
At euthanasia, RNA sequencing (RNA-Seq) analysis was performed in spleens and inguinal lymph nodes 
from imiquimod-treated mice. Gene expression was compared between WT, Padi2–/–, and Padi4–/– mice (Sup-
plemental Tables 1–4). For Padi2–/–, 2,241 genes were significantly modified in the lymph nodes compared 
with WT, including 1,714 that were transcriptionally repressed and 527 that were upregulated. A total of  
957 genes were modified in the lymph nodes of  Padi4–/– mice when compared with WT. Among those, 529 
were downregulated and 428 were upregulated when compared with WT. Only 8.9% of the downregulated 
genes and 7.2% of the upregulated genes overlapped between Padi2–/– and Padi4–/– mice (Figure 5, A and B). 
A total of  2,126 genes were differentially regulated between Padi2–/– and Padi4–/– lymph nodes. The analysis 
of  spleens by RNA-Seq revealed that 1,913 genes were transcriptionally repressed and 467 were upregulated 
in Padi2–/– compared with WT, while 2,221 were repressed and 1,178 were upregulated in Padi4–/– compared 
with WT. The degree of  overlap of  differentially regulated genes in imiquimod-treated Padi2–/– and Padi4–/– 
mice, when compared with imiquimod-treated WT, was significantly higher for spleen than for lymph nodes, 
with 37.3% of overlap in downregulated genes and 15% of overlap in upregulated genes (Supplemental Fig-
ure 5). Furthermore, 2,288 genes were differentially regulated in Padi2–/– compared with Padi4–/– spleens.
Several relevant immune pathways were significantly highlighted in the lymph node pathway anal-
ysis (Supplemental Table 3). Pathways associated to type I and type II IFN signaling were significantly 
Figure 3. Imiquimod-treated Padi4–/– mice retain normal vasore-
laxation capacity. (A–C) Aortic rings were isolated from untreat-
ed and imiquimod-treated FVB (A), Padi2–/– (B), and Padi4–/– (C) 
mice. Acetylcholine-dependent relaxation following phenyleph-
rine (PE) precontraction was determined. n = 6–10 mice/group. 
Results represent mean ± SEM % vasorelaxation; ****P < 0.0001. 
A 2-way ANOVA with post-hoc Tukey’s test was used to compare 
differences between the groups.
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downregulated in Padi2–/– compared with WT, while the upregulated pathways included leukocyte and 
neutrophil migration, as well as chemotaxis. In contrast, there were no significant canonical pathways 
differentially downregulated in the Padi4–/– lymph nodes compared with WT following in vivo imiquimod 
exposure. Among the pathways upregulated in the Padi4–/– compared with WT, those related to angiogen-
esis and epithelial cell proliferation were significantly changed (Supplemental Figure 4 and Supplemental 
Table 3), while pathways differentially regulated between Padi2–/– and Padi4–/– mice included neutrophil 
migration, chemotaxis, and activation ( downregulated in Padi4–/–), as well as protein folding and RNA 
splicing (downregulated in Padi2–/–) (Figure 5).
Genes downregulated in the Padi2–/– lymph nodes compared with WT lymph nodes were enriched with 
19 transcription factors with a binding site in the promoter of genes differentially regulated (Supplemental 
Table 5). Several of these transcription factors, including Irf7, Stat1, Irf1, Irf9, and Irf8, are key transcriptional 
regulators of type I IFN–dependent immune responses and/or type I IFN signaling. Irf7 was the most signifi-
cantly downregulated transcription factor in Padi2–/– lymph nodes. With regard to Padi4–/– lymph nodes, 8 tran-
scription factors had a binding site in the promoter of genes differentially regulated when compare with WT, 
including upregulation of Gata2, Cebpd, Foxf1, and Hoxd8 and dowregulation of Fhl2. In contrast to what was 
observed in Padi2–/–, these transcription factors target a significantly lower number of molecules (Supplemental 
Table 6). These results indicate that PAD2 is associated with more robust effects on gene transcription in lymph 
nodes when compared with PAD4 and that the pathways regulated in this lymphoid organ significantly differ 
between PAD2 and PAD4. These results further support that the protective effects observed in TLR-7–induced 
autoimmunity in the PAD2- and PAD4-deficient models are mediated by different pathways.
The pathway analysis of  the genes differentially regulated by lack of  Padi2–/– or Padi4–/– in the spleen 
of  imiquimod-treated mice revealed a different profile when compared with findings in lymph nodes (Sup-
plemental Figure 5 and Supplemental Tables 2 and 4). For Padi2–/– mice, the top downregulated pathways 
included ribonucleoprotein complex biogenesis and RNA processing and splicing, while the top upregulated 
pathways were associated to autophagy and organelle disassembly (Supplemental Figure 5 and Supplemental 
Table 4). In Padi4–/– mice, the top downregulated pathways similarly included RNA processing and ribonuc-
leoprotein biogenesis, as well as DNA replication, while upregulated pathways were associated to T cell acti-
vation and differentiation (Supplemental Figure 5 and Supplemental Table 4). When comparing Padi2–/– and 
Padi4–/–, the top downregulated pathways in Padi2–/– were those related to cytoplasmic translation and intra-
cellular transport across organelles, ER stress, and glycoprotein metabolic processes, while downregulated 
pathways in the Padi4–/– included autophagy and organelle disassembly pathways (Supplemental Figure 5).
The differentially expressed genes in the Padi2–/– spleens compared with WT spleens were enriched 
with 13 transcription factors with a binding site in the promoter of  genes differentially regulated (Sup-
plemental Table 7). Among them, Mycn (downregulated), Crem (downregulated), and Klf3 (upregulated) 
accounted for the ability to interact with a large number of  genes differentially regulated in the RNA-Seq 
analysis. In Padi4–/– spleens, 23 transcription factors had a binding site in the promoter of  genes differen-
tially regulated compared with WT, including downregulation of  Nfe2l2, Ppargc1a, Ccne1, E2f3, and Nrf1 
and upregulation of  Id2, Id3, Hdac1, and Hdac2 (Supplemental Table 8). Finally, the differentially expressed 
genes in the Padi2–/– lymph nodes or spleens compared with Pad4–/– were enriched with 23 (lymph nodes) 
and 16 (spleen) transcription factors with a binding site in the promoter of  genes differentially regulated 
(Supplemental Tables 9 and 10). These transcription factors included molecules implicated in type I IFN 
signaling, antigen presentation, oxidative stress, and neutrophil differentiation. These results indicate that 
the lack of  PAD2 and PAD4 in spleen led to a distinct transcriptional profile regulation compared with 
lymph nodes and with broader overlap between PAD2 and PAD4 regulation than in lymph nodes.
Alterations in T cell responses in imiquimod-treated Padi2–/– and Padi4–/– mice. To further investigate putative 
NET-independent roles on the modulation of  PAD2 and PAD4 in TLR-7–induced lupus autoimmunity, 
Figure 4. Padi4–/– neutrophils generate NETs lacking citrullinated Histone 3 (Cit-H3) and do not promote vascular damage. (A and B) BM neutrophils of naive 
FVB, Padi2–/–, and Padi4–/– mice were stimulated with the calcium ionophore A23817 for 2 hours to induce NET formation and stained for Cit-H3 (A) and MPO 
(B). Total magnification is 40×. (C) Lack of Cit-H3 in Padi4–/– NETs was confirmed by Western blot of imiquimod-induced NETs. Results are representative of 
3 experiments (D). Aorta rings were cultured in the presence of imiquimod-induced NETs prior to assessment of vasorelaxation capacity. Results represent 
% mean ± SEM vasorelaxation, n = 3 mice/group. (E) Splenocytes from naive FVB, Padi2–/–, and Padi4–/– mice (n = 3/group) were cultured for 24 hours in the 
presence of imiquimod-induced NETs, and the expression of type 1 IFN–inducible genes was analyzed by RT-PCR. *P < 0.05, **P < 0.005. Statistical analysis 
was performed with 2-tailed unpaired t test. For D, analysis was by 2-way ANOVA with post-hoc Tukey’s test to compare differences between the groups; *P < 
0.05 for PAD4 KO vs. FVB; #P < 0.05 for PAD4 KO vs. PAD2 KO.
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and given that some of  the differentially regulated genes were expressed in lymphocytes (Supplemental 
Tables 1 and 2), we purified naive and memory T cells from the various strains exposed to imiquimod. 
Padi2 mRNA was expressed in both naive and mouse memory T cells at comparable levels, while Padi4 
mRNA was detected in memory, but not naive, T cells (Supplemental Figure 6A). As expected, PAD2 
protein was detected in murine CD4+ T cells in Padi4–/– and FVB CD4+ T cells but not in Padi2–/– T cells 
(Figure 6). PAD4 protein could not be detected in T cells from any of  these mouse strains using commer-
cially available antibodies (not shown).
As levels of  expression of  Padi2 are low in neutrophils and NET formation was not impaired in the 
absence of  this molecule, we explored whether some of  the protective effects observed in Padi2–/– were related 
Figure 5. PAD2 and PAD4 differentially regulate gene expression in secondary lymphoid organs. (A) MA plots of gene expression data in lymph nodes 
following in vivo imiquimod exposure between Padi2–/–, Padi4–/–, and WT FVB (WT) (n = 4 mice/group). Differential expression was calculated by ANOVA test 
on normalized gene counts. Genes with P < 0.05 are colored in red. (B) Venn diagrams depicting the number of significantly downregulated and upregulated 
genes between Padi2–/– or Padi4–/– and WT lymph nodes. (C) Gene Ontology (GO) biological pathway analysis of significant genes between Padi4–/– and Padi2–/– 
lymph nodes. Statistical analysis of functional profiles for genes and related pathways was performed using the clusterProfiler package in RStudio.
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to modulation of  T cell responses. Th1 and Th17 responses were downregulated in an ex vivo analysis of  
imiquimod-treated Padi2–/– and Padi4–/– mice compared with treated FVB mice (Figure 7, A and B). While 
no PAD4 protein expression was detected in total CD4+ T cells, Padi4–/– T cells displayed decreases in IFN-γ–
producing CD4+ T cells compared with WT following in vivo imiquimod exposure. These effects were also 
observed, but were less profound, in Padi2–/– mice. These results indicate that both PAD2 and PAD4 modulate 
in vivo murine T cell polarization. Given the differences in cellular expression of  these PADs, the modulation 
of  T cell function in the absence of  PAD4 could be an indirect effect from other PAD4-expressing innate 
cells on T cell function in vivo, consistent with what has been observed in other inflammatory models. To 
further define whether PAD4’s effect on T cell function is an extrinsic phenomenon, in vitro induction of  T 
cell polarization in FVB WT, Padi2–/–,and Padi4–/– mice was compared. Consistent with in vivo experiments, 
Padi2–/– T cells showed impaired abilities to polarize to Th1 and Th17 cells, while this was not the case for 
Padi4–/– T cells (Figure 7C). These results support that the in vivo impairments in mouse T cell polarization 
observed in the Padi4–/– T cells were secondary to a lack of  PAD4 on other immune cell types that modulate 
T cell function, rather than on an intrinsic T cell defect. In contrast, the defects observed in T cell polarization 
in Padi2–/– murine T cells appear to be, at least in part, T cell intrinsic.
PAD2 and PAD4 are expressed in human CD4+ T cells and modulate their function. We next investigated 
whether PAD expression in human T cells was similar to their murine counterparts. By flow cytometry, 
we detected PAD2 expression in CD14+ healthy control monocytes, consistent with previous reports (45). 
While we did not find detectable PAD2 protein in CD15+ human neutrophils, this protein was present in 
CD4+ healthy control T cells (Figure 8A). PAD2 expression was also confirmed in purified SLE CD4+ T 
cells by Western blot and immunofluorescence (Figure 8, B and C) with no obvious difference in the levels 
of  this isozyme when comparing control and lupus (Supplemental Figure 6B). Consistent with previous 
reports, CD15+ neutrophils expressed high levels of  PAD4, and in contrast to mouse T cells, low levels of  
PAD4 protein were detected in human CD4+ T cells (Figure 8D). Furthermore, human memory CD4+ T 
cells expressed higher levels of  both PAD2 and PAD4 protein when compared with naive CD4+ T cells 
(Supplemental Figure 6C). Human and SLE T cells displayed similar levels of  PAD4 (Supplemental Fig-
ure 6B). Overall, these results suggest different expression of  PADs when comparing mouse with human 
CD4+ T cells and activation status of  the cell. To test whether PADs are involved in T cell polarization and 
cytokine production in human T cells, isolated CD4+ T cells were exposed to the PAD2-specific inhibitor 
AFM30a (46) and the PAD4-specific inhibitor GSK199 (47). The compounds did not induce CD4+ T cell 
cytotoxicity at the doses tested, as activation and apoptosis were not affected (Supplemental Figure 7). 
Human naive CD4+ T cells polarized to Th1 and Th17 phenotypes in the presence of  these PAD2- and 
PAD4-specific inhibitors displayed significant reduction in IFN-γ production at the mRNA and protein lev-
el (Figure 8E), while Th17 polarization was not affected (not shown). These results indicate that, in human 
T cells, both PAD2 and PAD4 modulate T cell function and inhibit Th1 responses.
Figure 6. PAD2 expression in murine CD4+ T cells. (A and B) Splenocytes isolated from naive FVB, Padi2–/–, and Padi4–/– mice were sorted, and PAD2 
expression was quantified by Western blot and densitometry. Data are shown as mean ± SD; 2 mice per group (1 and 2).
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Figure 7. Reduced in vivo Th1 and Th17 responses in imiquimod-treated Padi2–/– and Padi4–/– mice. (A and B) Splenocytes from untreated and imiqui-
mod-treated (IMQ-treated) FVB, Padi2–/–, and Padi4–/– mice were stimulated in vitro with PMA and ionomycin, and CD4+ T cell cytokine production was 
measured by flow cytometry to determine Th1 (A) and Th17 (B) responses. Box-and-whisker plots show median, lower and upper quartiles, and minimum 
and maximum % values and are representative of 2 independent experiments, each performed in 4-6 mice/group. *P < 0.05, **P < 0.005, ****P < 0.0001. 
(C) Splenic naive T cells from FVB, Padi2–/–, and Padi4–/– mice were activated by α-CD3 and α-CD28 in the presence/absence of polarizing cytokines and 
antibodies. At day 5, the cells were analyzed for gene expression levels of Ifng in Th1 conditions and Il17a in Th17 conditions; n = 4. Box-and-whisker plots 
show median, lower and upper quartiles, minimum and maximum fold induction relative to polarization response in FVB mice. *P < 0.05, **P < 0.005. 
Statistical analysis was performed by 2-tailed Mann-Whitney U test.
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Discussion
This study addressed the putative roles that specific PAD enzymes play in the development of  TLR-7–
dependent lupus autoimmunity and its associated organ and vascular damage (Supplemental Table 11). 
A nonautoimmune-prone mouse background (FVB) was selected to avoid any confounding effects of  pre-
existing immune cell defects. Importantly, circulating levels of  different leukocytes in untreated mice were 
not affected by the lack of  either enzyme, independent of  their background. Our results demonstrate that, 
following stimulation with TLR-7 agonists, Padi4–/– mice were significantly protected from a variety of  
features characteristic of  lupus autoimmunity, including autoantibody production, type I IFN responses, 
renal IC deposition, and endothelial dysfunction. In contrast, Padi2–/– mice displayed a more moderate 
protection in that they showed lower amounts of  autoantibodies and type I IFN responses when com-
pared with WT mice exposed to TLR-7 agonists, but they still exhibited prominent renal IC deposition 
and endothelial dysfunction. This is somewhat counterintuitive, as PAD2 is more ubiquitously expressed 
than PAD4 (45) and Padi2–/– showed more profound changes in gene expression in lymph nodes than 
Padi4–/– when compared with WT. Moreover, lack of  PAD2 or PAD4 did not affect total IgG levels but did 
selectively decrease levels of  various autoantibodies, suggesting that, within the total IgG pool, a subset of  
autoreactive antibody–producing cells may be preferentially affected by the lack of  PADs. Indeed, pathway 
analysis in lymph nodes suggested that the lack of  these molecules modulated canonical pathways of  great 
relevance in B cell ontogeny and activation.
Previously, pan-PAD inhibitors that block both PAD2 and PAD4 effects had been found to be protective 
in 2 genetically prone murine models of  lupus, with similar mitigation of  type I IFN responses, renal disease, 
and endothelial dysfunction (31, 32). While these compounds had been found to inhibit NET formation in 
these animal models, it remained unclear whether PAD4 would solely account for this inhibitory effect, as 
PAD2 has been reported to also be expressed in neutrophils and have nuclear localization. In the model test-
ed herein, neutrophils deficient in PAD2 were not impaired in their ability to form NETs, while the lack of  
PAD4 was associated with an inhibitory effect on the synthesis of  these traps. In the FVB background, how-
ever, the lack of  PAD4 still allowed for some neutrophils to form NETs. However, the NETs formed in the 
absence of  PAD4 had significantly reduced Cit-H3 and were found to be significantly less efficient at inducing 
endothelial dysfunction and type I IFN responses than NETs formed in the presence of  PAD4. Whether the 
decreases in Cit-H3 account for all or some of  these differences in the properties of  the NETs remains to be 
determined, as PAD4 has the ability to citrullinate several molecules present in neutrophils, including compo-
nents of  the NF-κB pathway, vimentin, and other histones (27). In contrast, NETs formed in the absence of  
PAD2 appeared to retain their ability to damage the endothelium but were less interferogenic when compared 
with NETs formed in WT neutrophils. While there are some similarities in the proteins targeted for citrulli-
nation by PAD2 and PAD4, some proteins are selectively targeted, and this could account for the differences 
in the properties of  the NETs. A recent report indicates that Cit-H3 promotes dysfunction of  the endothelial 
barrier through reorganization of  the actin cytoskeleton (48), and this may explain why mice lacking Padi4 
generate NETs devoid of  vasculopathic effects. Future studies in mice that genetically lack both PAD2 and 
PAD4, as well as in vivo use of  PAD2- and PAD4-specific inhibitors, will be required to assess whether dual 
blockade of  these pathways promotes synergistic effects in the modulation of  autoimmunity and endothelial 
dysfunction when compared with inhibition of  single isozymes, given the effectiveness previously observed 
with pan-PAD inhibitors in other lupus mouse models (31, 32). It will also be important to further assess the 
putative specific roles of  PAD2 and PAD4 in disease phenotype in human SLE.
The mechanism explaining why the absence of  PAD2 does not significantly protect mice from IC 
deposition in the kidney is unclear. Mice lacking either PAD2 or PAD4 had decreases in anti-dsDNA auto-
antibodies. As we previously proposed for similar observations made using pan-PAD chemical inhibitors, 
it is possible that decreased NET formation, as occurs in Padi4–/– but not in Padi2–/–, lowers the amounts of  
generated autoantigens required for IC formation (31). This, combined with lower anti-dsDNA synthesis 
in these mice, may lead to a decrease in renal IC deposits. In contrast, given that Padi2–/– are less protected 
from enhanced NET formation, they may generate sufficient amounts of  autoantigen to increase IC depo-
sition, even if  some types of  autoantibodies decrease.
Two recent studies in other mouse models of  lupus recently challenged the concept that PAD4 is 
an important target in SLE (34, 35). However, some of  the models used, like the MRL/lpr model, are 
primarily characterized by the expansion of  aberrant autoreactive T cells due to a lack of  functional Fas 
(49). Given that we did not find that PAD2 and PAD4 inhibitors affected T cell survival, it is possible 
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that the lack of  PAD4 is not sufficient to abrogate disease in a model primarily driven by aberrant auto-
reactive T cells. Indeed, previous studies suggest that dual inhibition with a pan-PAD inhibitor, which 
may target T cells more effectively given our observations in the current study, mitigates renal disease, 
skin involvement, and immune dysregulation in MRL/lpr (32). Given that PAD2 is the primary PAD 
expressed in murine T cells, it is not surprising that single deletion of  PAD4 would not alter the natural 
history of  lupus in this model. In the same manuscript, the authors also reported that the anti–glomerular 
Figure 8. PAD2 and PAD4 are expressed on human T cells and modulate Th1 responses. (A) PAD2 protein expression levels (by geometric mean fluores-
cent intensity, MFI, relative to isotype control) in healthy control human neutrophils (CD15+), monocytes (CD14+), and T cells (CD3+CD4+). Box-and-whisker 
plots show median, lower and upper quartiles, and minimum and maximum MFI values of 5 independent experiments. (B and C) PAD2 protein expression 
quantified in SLE CD4+ T cells by Western blot (B) and immunofluorescence (C). In B, each lane represents an individual SLE subject (n = 4). C is a represen-
tative microphotograph of lupus CD4+ T cells (n = 2); magnification is 40×. (D) PAD4 protein expression levels assessed by geometric MFI relative to isotype 
control in healthy control human neutrophils (CD15+), monocytes (CD14+), and T cells (CD3+CD4+). Box-and-whisker plots show median, lower and upper 
quartiles, and minimum and maximum MFI values of 5 independent experiments. (E) Sorted healthy donor naive CD4+ T cells were activated with α-CD3 
and soluble α-CD28 and polarized for 5 days in the presence or absence of the PAD2 inhibitor AFM30a or the PAD4 inhibitor GSK199. Left graph shows 
box-and-whisker plots displaying median, lower and upper quartiles, and minimum and maximum MFI values of IFN-γ in Th1 conditions, and right graph 
displays box-and-whisker plots with median, lower and upper quartiles, and minimum and maximum mRNA fold induction of IFNG in Th1 conditions rela-
tive to untreated control; n = 5 healthy controls. Statistical analysis was performed by 2-way ANOVA with Dunnett’s multiple comparisons test. 
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basement membrane (anti-GBM) nephritis model was not protected when a pan-PAD inhibitor was 
administered (34). It is important to note that the anti-GBM model is more reminiscent of  a rapidly pro-
gressive glomerulonephritis than of  classic lupus nephritis and also lacks many of  the features of  SLE 
such as anti-dsDNA autoantibodies or type I IFN responses (50). In the anti-GBM model, neutrophils 
are abundant in the kidney (51), while they are fairly scant in renal tissue of  genetically driven murine 
lupus models and in human SLE (21, 31, 52). It is also important to note that — when there is very 
significant influx of  neutrophils into a tissue and, therefore, high neutrophil density — NETs undergo 
a phenomenon of  aggregation (53) that can lead to an antiinflammatory effect due to the cleavage of  
inflammatory molecules by neutrophil proteases. NET aggregation is a common finding of  conditions 
such as gout (53) or the peritoneum of  pristane-induced lupus (35), but it is not characteristic of  other 
murine lupus models or human SLE (21, 31). Therefore, the proinflammatory versus antiinflammatory 
effects of  NETs are very likely context dependent and may explain, at least in part, both the discrepant 
effects observed in the various mouse models studied and the heterogeneity of  human SLE.
An additional aspect of  this study is the characterization of  the role of  PAD2 and PAD4 in T 
cell responses in TLR-7–dependent autoimmunity and in human T cells. While both Padi2 and Padi4 
mRNA were detected in memory murine T cells, PAD4 protein was not. This is consistent with 
results from a previous study on the role of  PAD4 in the glucose-6-phosphate isomerase–induced 
(GPI-induced_ arthritis model where impairments in Th17 cell differentiation observed in Padi4–/– 
were also due to an extrinsic factor during GPI immunization, rather than to intrinsic defects in 
Padi4–/– murine CD4+ T cells (54). In contrast, the effects of  PAD2 on T cell polarization appear to be, 
at least in part, intrinsic, given that T cell polarization in the context of  PAD2 deficiency was inhib-
ited in vivo and in vitro. Importantly, the effect of  PAD4 on human T cells differs from mice. Both 
PAD4 and PAD2 protein were found to be expressed in human T cells, with memory T cells express-
ing higher levels than naive T cells. Importantly, both PAD2- and PAD4-specific inhibitors were able 
to decrease Th1 polarization in vitro, suggesting that these compounds may target Th1-driven immu-
nity. This is a relevant finding in the context of  several autoimmune diseases that are driven by both 
abnormalities in the innate and adaptive immune arms, such as SLE. Th1 cells have been described 
to play important roles in SLE and in lupus-associated organ damage such as lupus nephritis (55, 56). 
Therefore, targeting Th1 cells by PAD inhibition may add a beneficial protective effect in SLE. It will 
be important in future studies to understand the molecular mechanisms by which PADs impact Th1 
polarization. Of  note, a recent study described PAD2 expression in human neutrophils (28). In our 
studies, we were not able to detect PAD2 protein in human neutrophils. This could be explained by 
the recent observation that PAD2 is actively secreted by neutrophils, supporting why PAD2 was not 
detected by intracellular flow (28).
Detailed RNA-Seq analysis revealed distinct transcriptional modulation in response to in vivo TLR-7 
stimulation when comparing lymph nodes and spleens in mice lacking PAD2 and PAD4. The differences 
observed between the pathways modulated in spleens and lymph nodes by these PADs are likely the reflec-
tion of  the cells that are most predominant in these organs following TLR-7 stimulation. Future studies 
should further address how these PADs modulate gene expression and cellular function, including metabo-
lism, in specific cell subsets purified from lymphoid organs. The pathway analysis does support that PAD4 
influences autoimmunity, at least in part, through significant modulation of  neutrophil responses, while 
PAD2 may be relevant to inflammation through regulation of  other myeloid cell responses and changes in 
the adaptive immune compartment. Future studies should systematically investigate the mechanisms lead-
ing to differential regulation of  gene expression mediated by different PADs in immune cells using purified 
cell subsets and epigenetic analyses to further assess differential contributions of  each PAD to innate and 
adaptive immune responses.
In summary, we have identified differential regulation and modulation of  autoimmune responses, 
gene expression in secondary lymphoid organs, and endothelial dysfunction by the isozymes PAD2 and 
PAD4 in TLR-7–dependent autoimmunity and in potentially pathogenic T cell responses. Given that both 
isozymes appear to play differential roles in the modulation of  immune responses, the use of  chemical 
inhibitors that target both PAD2 and PAD4 should be further examined for the potential to provide com-
plimentary therapeutic effects in the treatment of  autoimmune conditions characterized by aberrant innate 
and adaptive immune responses such as SLE.
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Methods
Animals. WT FVB mice were obtained from the Jackson Laboratory and housed at the NIAMS animal 
facility throughout the experimental period. KO mice were generated in the FVB genetic background. 
The gene-trapped Padi2-null mice were obtained from the Texas Institute for Genomic Medicine. Padi2-
null mice were generated by partial replacement of  the first coding exon with the IRES/bGoe/PolyA 
cassette via homologous recombination. The deleted genomic sequence is as follows: 5′ - GCAGCCG-
CCTATACGGGAAAATATGCTGCGGGAACGGACCGTGCGGCTGCAGTATGGGAGCCGC-
GTGGAGGCGGTGTACGTGCTGGGCACGCAGCTCTGGACCGATGTCTACAGGTGAGC-
CGAGAGAGAGTTACCCTCTCACCTACCCTTCACAAATCTTGAG - 3′. To generate the Padi4-null 
mice, the genomic sequence of  Padi4 from the ATG start site to approximately 100 bp downstream of the 
TGA stop codon was replaced in frame (with respect to the Padi4 initiation codon) by the coding sequence 
of  LacZ and a Lox-flanked neomycin gene driven by the PGK-EM7 promoter. The deleted genomic 







GGGGCAGTTTGGGGCAGGCAGGAGCTGGGCGCTGCTG - 3′. Genotyping confirmed the genetic 
background of  these strains.
Human subjects. Patients fulfilled the American College of  Rheumatology revised diagnostic criteria 
for SLE (57), and more than 90% were females. Disease activity was assessed by the SLE Disease Activ-
ity Index (SLEDAI) score (58). The mean SLEDAI was 4 (range 1–18), indicating mild disease activity. 
Peripheral blood was drawn by venipuncture in EDTA-containing tubes. Human PBMCs were isolated by 
Ficoll-Paque Plus (GE Healthcare) density gradient.
Generation of  imiquimod-induced lupus model. Female 6- to 8-week-old mice were treated topically with 
the TLR-7 agonist imiquimod, which induces systemic autoimmunity with lupus-like characteristics in var-
ious non–autoimmune-prone mice strains (37, 41). Imiquimod cream 5% (E Fougera & Co) was applied to 
both ear folds of  WT, Padi2–/–, and Padi4–/– FVB mice 3 times a week. During the third week of  treatment, 
mice were exposed to a subacute dose of  300 mJ/cm2 UVB-narrowband radiation on shaved dorsal skin for 
5 consecutive days. Disease severity was analyzed after 6 weeks from the onset of  treatment.
Quantification of  blood cell counts and autoantibodies. Whole blood was collected at euthanasia by cardiac 
puncture, and serum was purified. Complete blood counts were measured at the Department of Laboratory 
Medicine (NIH). Commercially available ELISA kits were used to quantify serum anti-dsDNA and total IgG 
levels (Alpha Diagnostic International), per manufacturer’s instructions. Serum anti-RNP/Sm and anti-his-
tone autoantibodies were also determined by ELISA, as described (45). Nunc MaxiSorp ELISA plates were 
precoated with recombinant RNP/Sm (RNP/Sm; 20 mg/ml, ImmunoVision) or calf  thymus histone (20 mg/
ml, MilliporeSigma) in PBS at 4°C overnight. Plates were blocked with 3% FCS for 1 hour at 37°C, washed, 
and incubated with 1:100 dilutions of mouse sera for 1 hour at 37°C. Plates were washed, and specific antibod-
ies were detected with a 1/1000 dilution of alkaline phosphatase–conjugated goat anti–mouse IgG (103605; 
Southern Biotech) for 1 hour at 37°C and developed with a phosphatase substrate for 30 minutes at 37°C.
Renal disease assessment. Urine samples were collected at euthanasia, and albumin/creatinine ratio was quan-
tified using the Albuwell and Creatinine Companion kits (Exocell). Kidneys were perfused with saline and pre-
served in OCT compound. For glomerular IC analysis, frozen sections were analyzed for C3 and IgG deposi-
tion. Frozen tissue samples were stained with FITC-conjugated anti-C3 (ICL) and Alexa Fluor 594–conjugated 
anti-mouse IgG (Thermo Fisher Scientific) for 1 hour at 4°C. DNA was visualized using Hoechst (Thermo 
Fisher Scientific). ICs were scored in a blinded fashion as described (59). A scale of 0–3 was assigned for both 
C3 and IgG deposition based on intensity of signal, as follows: 0, normal (no staining); 1, mild; 2, moderate; and 
3, severe. A minimum of 10 glomeruli were scored per mouse, and the individual average scores were reported. 
Quantification of renal inflammation and damage was performed by a veterinary pathologist as described (59).
Neutrophil isolation and NET formation assay. BM-derived neutrophils were isolated from untreated FVB, 
Padi2–/–, or Padi4–/– mice by negative selection using EasySep Mouse Neutrophil Enrichment Kit (Stemcell Tech-
nologies). Neutrophils (1 × 105 ) were allowed to adhere to coverslips coated with poly-L-lysine (MilliporeSigma) 
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and were then treated with the calcium ionophore A23187 (50 μM; Thermo Fisher Scientific) in serum-free 
RPMI 1640 (Thermo Fisher Scientific) for 2 hours at 37°C. Neutrophils were then fixed in 4% paraformalde-
hyde in PBS (Thermo Fisher Scientific) at 4°C overnight. Nonspecific binding was blocked with 0.02% porcine 
skin gelatin (MilliporeSigma) in PBS for 30 minutes. Cells were incubated with anti-MPO (1:1000; Agilent 
Technologies) or anti–Histone H3 (citrulline R2 + R8 + R17; Cit-H3; 1:250; Abcam) diluted in blocking solution 
for 1 hour at 37°C in a humidified chamber. After 3 washes, coverslips were incubated with Alexa Fluor 488– or 
Alexa Fluor 555–conjugated secondary antibodies (1:500; Thermo Fisher Scientific) diluted in blocking solution 
for 30 minutes at 37°C in a humidified chamber. Hoechst-stained (1:1000) coverslips were mounted onto glass 
slides with ProLong Gold Antifade Mountant (Thermo Fisher Scientific) and visualized after curing overnight. 
The frequency of NET-forming neutrophils was quantified by determining the number of neutrophils extruding 
DNA and containing at least 1 protein associated with NETs (i.e., MPO and/or CitH3), in relation to the total 
number of neutrophils analyzed. A minimum of 3 images were quantified per sample.
NET isolation and protein analysis. Neutrophils were isolated from untreated FVB, Padi2–/–, or Padi4–/– mice 
and stimulated with imiquimod (R837; 100 μg/ml; InvivoGen) in serum-free RPMI 1640 for 6 hours at 37°C. 
NETs were isolated as previously described (47) using 10 U/ml of  micrococcal nuclease (Thermo Fisher 
Scientific) for 15 minutes at 37°C (48). NETs were centrifuged to remove cellular debris and the supernatants 
stored at –80°C until used. NETs were separated using a NuPAGE 4-12% Bis-Tris Protein Gel (Thermo 
Fisher Scientific) and transferred onto a nitrocellulose membrane (Bio-Rad). The membrane was blocked 
with 10% BSA for 30 minutes at room temperature (RT) and was then incubated with a mouse monoclonal 
antibody targeting total Histone H3 (Abcam) and a rabbit polyclonal antibody specific for Cit-H3 (Abcam) 
overnight at 4°C. The membrane was washed 3 times with PBS-Tween (0.1%) and incubated with secondary 
antibodies coupled to IRDye 800CW and IRDye 680RD (Thermo Fisher Scientific) accordingly. After 3 addi-
tional washes, the membrane was developed using a Li-COR Odyssey Clx scanner (Li-COR Biosciences).
Endothelium-dependent vasorelaxation assays. Studies were performed as described by our group (59). After 
euthanasia, endothelium-intact aortic rings (~2 mm) were excised and mounted in a myograph system (Dan-
ish Myo Technology A/S) containing physiological salt solution (PSS) with aeration (95% O2/5% CO2). 
Aortic rings were subsequently set at 700 mg passive tension and equilibrated for 1 hour with buffer changes 
every 20 minutes. Contraction was achieved with PSS containing 100 mM potassium chloride (KPSS) pri-
or to collecting contraction/relaxation measurements. Phenylephrine-induced (PE-induced) contraction was 
allowed to reach a stable plateau. Vasorelaxation was assessed by addition of  Ach (1 × 10−9 M to 1 × 10−5 M). 
To assess endothelial dysfunction induced by NETs, FVB aortas were incubated with imiquimod-generated 
NETs for 15 minutes prior to the vasorelaxation assay. Similar amounts of  NETs were included in the assay, 
as shown by total histone H3 analysis (Figure 4C). Results were reported as percentage of  PE contraction.
Extracellular flux assay. A total of  3 × 105 BM mouse neutrophils were seeded onto poly-L-lysine–coated 
Seahorse XF96 microplates in glucose-free XF Base Medium (Agilent Technologies) supplemented with 4 
mM GlutaMAX (Thermo Fisher Scientific) and 1 mM sodium pyruvate (Thermo Fisher Scientific). The 
XF96 Analyzer (Agilent Technologies) was used to assay the cells. Glucose (MilliporeSigma) was injected 
in Port A at a final concentration of  25 mM, and 2-Deoxy-D-glucose (2-DG; MilliporeSigma) was injected 
in Port C at a final concentration of  100 mM. Data were analyzed with the Wave Desktop software. The 
extracellular acidification rate (ECAR) was used as an indicator of  glycolysis. Glycolysis was defined as the 
ECAR at baseline subtracted from the ECAR after glucose injection.
Splenic proinflammatory cell analysis. Mouse splenocytes were isolated from untreated and imiquim-
od-treated FVB, Padi2–/–, or Padi4–/– mice and stimulated in vitro with phorbol 12-myristate 13-acetate 
(PMA; 50 ng/ml; MilliporeSigma) and ionomycin (750 μg/ml; MilliporeSigma) for 3 hours. Brefeldin 
A (BFA; BioLegend) was added for an additional hour, and LIVE/DEAD Fixable Blue Dead Cell Stain 
Kit (Thermo Fisher Scientific) was used to label dead cells prior to incubating with FcR Blocking Reagent 
(Miltenyi Biotec). Splenocytes were stained with anti–CD3-PE-Cy5 (145-2C11) and anti–CD4-Brilliant 
Violet 605 (RM4-5). The Fixation/Permeabilization Solution Kit (BD Biosciences) was used before intra-
cellular staining with anti–IL-17A (TC11-18H10.1) and anti–IFN-γ (XMG1.2). All antibodies were from 
BioLegend. Data were collected with the BD LSRFortessa (BD Biosciences) and analyzed with FlowJo.
Mouse T cell activation and polarization assays. Naive CD4+CD62L+CD44– T cells were isolated from 
10-week-old FVB, Padi2–/–, or Padi4–/– spleens by sorting with FACSAria IIIu. Cells were stimulated for 4 
hours with PMA (50 ng/ml) and ionomycin (750 μg/ml), with the addition of  BFA, and processed with the 
Fixation/Permeabilization Solution Kit after surface staining. Cells were stained with anti–CD4-BV421 
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(GK1.5), anti–CD62L-PE (MEL-14), anti–CD44-APC-Cy-7 (IM7), anti–IFN-γ–FITC (XMG1.2), and 
anti–IL-17A-APC (TC11-18H10.1). All staining antibodies were purchased from BioLegend. Data were 
collected with the BD LSRFortessa and analyzed with FlowJo.
Mouse T cell in vitro polarization was performed as described (60). CD4+CD62L+CD44– naive splenic 
T cells from 10-week-old FVB, Padi2–/–, or Padi4–/– mice were sorted using FACSAria IIIu and activated by 
plate-bound 10 μg/ml α-CD3 and 10 μg/ml α-CD28 (BioLegend) in T cell culture medium (RPMI1640 with 
10% FBS [Gemini Bio], 2 mM glutamine [Thermo Fisher Scientific], penicillin [100 IU/ml] [Thermo Fisher 
Scientific], streptomycin [0.1 mg/ml] [Thermo Fisher Scientific], 10 mM HEPES [MilliporeSigma], 1 mM 
sodium pyruvate [Thermo Fisher Scientific], and 50 μM β-mercaptoethanol [Bio-Rad]) for 3 days in the pres-
ence/absence of  various cytokines and antibodies as indicated. At day 3, cells were removed and rested with 
IL-2 and fresh cytokines for 2 more days. Conditions were as follows: (Th0) anti–IFN-γ (10 μg/ml; catalog 
506502, clone B27) and anti–IL-4 (10 μg/ml; catalog 500707, clone 8D4-8); (day 3) IL-2 (100 U/ml; catalog 
589108), anti–IFN-γ (10 μg/ml), and anti–IL-4 (10 μg/ml); (Th1) IL-12 (10 ng/ml) and anti–IL-4 (10 μg/
ml); (day3) IL-2 (100 U/ml), IL-12 (10 ng/ml), and anti–IL-4 (10 μg/ml); and (Th17) IL-6 (20 ng/ml; catalog 
573008), TGF-β (3 ng/ml; R&D systems, catalog 240-B-010), IL-23 (50 ng/ml; catalog 574106), anti–IFN-γ 
(10 μg/ml), and anti–IL-4 (10 μg/ml). All antibodies were purchased from BioLegend. For intracellular cyto-
kine staining, cells were restimulated for 4 hours with PMA (50 ng/ml) and ionomycin (750 μg/ml), with 
the addition of  monensin (BD GolgiStop). Cells were stained for CD4, CD62L, CD44, IFN-γ, and IL-17A.
RNA-Seq. Inguinal lymph nodes and spleens were collected from imiquimod-treated mice at euthana-
sia and frozen at –80°C in Tri-Reagent (MilliporeSigma). RNA was isolated with Direct-zol RNA MiniPrep 
(Genesee El Cajon) and cDNA libraries prepared with poly (A) tail enrichment using NEBNext Ultra II RNA 
Library Prep Kit following manufacturer’s instructions (New England Biolabs; E7770S and E7490S). The 
fragmentation of the libraries was assessed with Agilent Technologies’ D1000 ScreenTape and concentration 
quantified with picogreen (Agilent Technologies). RNA-Seq data were generated with Illumina HiSeq3000 for 
50 cycles (single-end reads). Raw sequencing data were processed with bcl2fastq/2.17.1 to generate FastQ files. 
Adapter sequences were removed using trimgalore/0.4.5. Single-end reads of 50 bases were mapped to the 
mouse genome build mm10 using TopHat2.1.1 (61). Gene expression values (reads per kilobase exon per mil-
lion mapped reads; RPKM) were calculated with Partek Genomics Suite 6.6, which was also used for 1-way 
ANOVA analyses. Gene expression data were subsequently analyzed in R Studio with a P value cutoff  of 0.05. 
MA plots were generated using the ggplot2 package. Pathway analyses were performed using the clusterProfiler 
package and gene ontology (GO) database (62). Transcription factor analyses were generated with IPA (Inge-
nuity Pathway Analysis, QIAGEN, V01-10) software. The data has been deposited into GEO (GSE121751).
Real-time PCR. Splenocytes were isolated from untreated and imiquimod-treated FVB, Padi2–/–, or Padi4–/– 
mice. Cell pellets were collected in TRI Reagent (MilliporeSigma), and RNA was isolated with the Direct-zol 
RNA MiniPrep Kit (Zymo Research). RNA was transcribed into cDNA using iScript Reverse Transcription 
Supermix (Bio-Rad). CXF96 Touch Real-Time PCR Detection System was used to amplify the following 
transcripts: Ifna (forward, 5′ - AAG GAC AGG CAG GAC TTT GGA TTC - 3′; reverse, 5′ - GAT CTC GCA 
GCA CAG GGA TGG - 3′), Ifnb (forward, 5′ - AAG AGT TAC ACT GCC TTT GCC ATC - 3′; reverse, 5′ - 
CAC TGT CTG CTG GTG GAG TTC ATC - 3′), Irf7 (forward, 5′ - TCC AAG TCT CCG GCT AAG T - 3′; 
reverse, 5′ - TGC TGT TTG GAG ACT GGC TAT - 3′), and Mx1 (forward, 5′ - GAT CCG ACT TCA CTT 
CCA GAT GG; reverse, 5′ - CAT CTC AGT GGT AGT CAA CCC - 3′). Values were normalized to Gapdh 
expression, and fold change was shown as expression in imiquimod-treated mice relative to expression in 
untreated mice. To test the effects of  NETs of  type I IFN–related gene expression, FVB splenocytes were iso-
lated and cultured for 24 hours with and without imiquimod-generated NETs from FVB, Padi2–/–, or Padi4–/– 
neutrophils (5%). Imiquimod at a concentration corresponding to that present in the NET preparations was 
used as the vehicle control (5 μg/ml). Cells were collected and processed as described above. The following 
primer sets were used: Isg15 (forward, 5′ - CAG AAG CAG ACT CCT TAA TTC - 3′; reverse, 5′ - AGA CCT 
CAT ATA TGT TGC TGT G - 3′), Tbk1 (forward, 5′ - TTC TGG AAG TCC AGA CGC ATTG - 3′; reverse, 
5′ - ACT GGT GAT CTC TAT GCT GTC A - 3′), and Gapdh (forward, 5′ - ACC ACA GTC CAT GCC ATC 
AC - 3′; reverse, 5′ - TCC ACC ACC CTG TTG CTG TA - 3′). Samples were normalized to Gapdh, and fold 
change was expressed as treated (vehicle or NETs) compared with untreated cells.
To measure the expression of  PADs in murine T cells, 9-week-old female WT, Padi2–/–, and Padi4–/– 
FVB mice were treated topically with imiquimod for 2 weeks. Splenic CD4+CD62L+CD44– naive T cells 
and CD4+CD62L–CD44+ memory T cells were sorted using FACSAria IIIu, and expression of  the 2 genes 
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analyzed with Padi2- or Padi4-specific TaqMan Gene Expression Assays (Padi2 [Mm01341648_m1] and 
Padi4 [Mm01341658_m1]; Applied Biosystems) and normalized to 18s ribosomal RNA (Mm03928990_g1). 
Gene expression data were confirmed by protein analysis. CD4+ T cells were isolated from mice, and 
PAD2 was detected by immunofluorescence and Western blotting (Proteintech Group). For human T cells, 
healthy donor CD4+ T cells were stained with anti–CD4-BV421 (catalog 317434, clone OKT4, BioLeg-
end), –CD45RA-PerCP-Cy5.5 (catalog 304122, clone HI100, BioLegend), and –CD45RO-APC-H7 (catalog 
561137, clone UCHL-1, BD Biosciences) before sorting with the FACSAria IIIu. Naive T cells (CD4+C-
D45RA+CD45RO–) and memory T cells (CD4+CD45RA–CD45RO+) were collected in TRI Reagent, and 
RNA was isolated and transcribed as described above. PADI2 (Hs01042505_m1) and PADI4 (Hs01057483_
m1) were measured and normalized to 18S ribosomal RNA (Hs03003631_g1). For T cell polarization stud-
ies, T cells were collected and processed as described above. TaqMan Gene Expression Assays used were 
as follows; (mouse) 18S, Mm03928990_g1; ifng, Mm01168134_m1; and Il-17A, Hs00174383_m1; (human) 
18S, Hs03003631_g1 and IFNG, Hs00989291_m1.
Human CD4+ T cell isolation for Western blot and immunofluorescence. CD4+ T cells were purified from 
PBMCs with the CD4+ T Cells Isolation Kit (Miltenyi Biotec). Lysates were separated using a NuPAGE 
4-12% Bis-Tris Protein Gel and transferred onto a nitrocellulose membrane. After blocking with 10% BSA 
for 30 minutes at RT, the membrane was incubated with a PAD2-specific primary antibody (Proteintech 
Group) overnight at 4°C. The membrane was washed 3 times with PBS-Tween (0.1%) and incubated with 
a secondary antibody coupled to IRDye 800CW. After additional washing, the membrane was developed 
using a Li-COR Odyssey Clx scanner. A subset of  sorted cells was seeded onto coverslips coated with 
poly-L-lysine and fixed with 4% paraformaldehyde in PBS. Fixed cells were permeabilized with 0.1% Tri-
ton X-100 (MilliporeSigma), and nonspecific binding was blocked with 10% normal goat serum (NGS; 
Thermo FIsher Scientific) for 30 minutes at RT. Cells were stained in 1% NGS with the aforementioned 
PAD2-specific antibody for 1 hour at RT. After washing, the cells were stained with a secondary antibody 
conjugated with Alexa Fluor 488 for 30 minutes at RT. Hoechst-stained coverslips were then mounted onto 
glass slides with ProLong Gold Antifade Mountant and cured overnight before imaging.
Treatment of  human CD4+ T cells with PAD inhibitors. Purified CD4+ T cells from healthy donors were 
activated by plate-bound α-CD3 (2 μg/ml) and soluble α-CD28 (1 μg/ml) (BioLegend) in T cell culture 
medium (RPMI1640 with 10% FBS, 2 mM glutamine, penicillin [100 IU/ml], streptomycin [0.1 mg/ml], 
10 mM HEPES, 10 mM sodium pyruvate, and 50 μM β-mercaptoethanol) for 5 days in the presence/
absence of  AFM30a (46) (PAD2 inhibitor, 25 μM) and GSK 199 (47) (PAD4 inhibitor, 15 μM). CD4+ T cell 
activation and apoptosis were determined by CD69 staining and LIVE/DEAD Fixable Aqua Dead Cell 
Stain Kit (Thermo Fisher Scientific).
Human T cell in vitro polarization. Experiments were performed as described (60). Healthy donor 
CD4+ T cells were stained with the following antibodies before sorting using the FACSAria IIIu: anti–
CD4-BV421, –CD45RA-PerCP-Cy5.5, and –CD45RA-APC-Cy7 and sorted for naive T cells (CD4+C-
D45RA+CD45RO–) using FACSAria IIIu. Naive CD4+ T cells were activated by plate-bound anti-CD3 
(2 μg/ml) and soluble anti-CD28 (1 μg/ml) (BioLegend) in T cell culture medium (RPMI1640 [Thermo 
Fisher Scientific] with 10% FBS, 2 mM glutamine, penicillin (100 IU/ml), streptomycin (0.1 mg/ml), 10 
mM HEPES, 1 mM mM sodium pyruvate, and 50 μM β-mercaptoethanol for 7 days in the presence/
absence of  various cytokines, antibodies, and PAD inhibitors as indicated. Conditions were as follows: 
(Th0) anti–IFN-γ (10 μg/ml), anti–IL-4 (5 μg/m), anti–IL-10 (5 μg/ml), and IL-2 (100 U/ml); (Th1) 
IL-12 (10 ng/ml), anti–IL-4 (5 μg/ml), anti–IL-10 (5 μg/ml), and IL-2 (100 U/ml); and (Th17) IL-6 (20 
ng/ml), IL-1β (20 ng/ml), IL-23 (50 ng/ml), anti–IFN-γ (10 μg/ml), anti–IL-4 (5 μg/ml), and anti–IL-10 
(5 μg/ml). PAD inhibitors were AFM30a (PAD2 inhibitor, 25 μM) and GSK199 (PAD4 inhibitor, 15 
μM). For intracellular cytokine staining, cells were restimulated for 4 hours with PMA (50 ng/ml) and 
ionomycin (750 μg/ml), with the addition of  Monensin (BD GolgiStop). Cells were stained for CD4 
(BV421), CD3 (APC-Cy7), CD45RA+ (PerCP-Cy5.5), IL-17A (PE), and IFN-γ (FITC).
Intracellular staining in human PBMCs. Human PBMCs were isolated as described above, permeabilized 
with eBioscience Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher Scientific), blocked 
with Fc blocker (BioLegend) for 15 minutes, and stained for surface and intracellular markers: CD15 
(PE-Cy7), CD14 (FITC), and CD4 (APC-Cy7). Cells were permeabilized and stained with either rabbit 
isotype control (Invitrogen), PAD2 (Proteintech), or PAD4 (Abcam) for 30 minutes, followed by staining 
with PE-conjugated donkey anti–rabbit IgG (BioLegend).
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Statistics. Data were plotted and analyzed using the GraphPad Prism 6 software. Statistical significance 
was calculated by 2-tailed Student’s t tests or, for non-Gaussian distributions, using the Mann-Whitney U 
test. For the vasorelaxation experiments, 2-way ANOVA with post-hoc Tukey’s test was used to compare 
differences between the groups. P < 0.05 was considered statistically significant.
Study approval. Healthy controls and subjects with a diagnosis of  SLE were recruited at the Clinical Cen-
ter, NIH. All individuals signed informed consent under NIAMS/NIDDK IRB–approved protocol, NIH 
94-AR-0066. All mouse experiments were approved by the NIAMS Animal Ethics Committee (ACUC).
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